Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer
Hans‐Joachim Wilke(Helmholtz-Institute Ulm), S. Seeber, Manuel Lösch(West German Heart and Vascular Center Essen), Wilfried Eberhardt(National Center for Tumor Diseases), J. Hayungs(West German Heart and Vascular Center Essen), U. Klaassen(West German Heart and Vascular Center Essen), R. Becher(West German Heart and Vascular Center Essen), U. Vanhoefer, W. Achterrath(Messer (Germany)), A. Harstrick(Merck KGaA, Darmstadt (Germany)), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin)
Cited by 23
Related Papers
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
|Journal of Clinical Oncology|2017|872
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
|The Lancet Oncology|2011|574